1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Basilea Pharmaceutica AG
  6. News
  7. Summary
    BSLN   CH0011432447

BASILEA PHARMACEUTICA AG

(BSLN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Basilea Announces Completion of Patient Enrolment in Phase 3 Eradicate Study Investigating Ceftobiprole in Bloodstream Infections

01/11/2022 | 01:15am EDT

Basilea Pharmaceutica AG announced the completion of patient enrolment into the phase 3 ERADICATE study. This study is investigating ceftobiprole in the treatment of patients with complicated bloodstream infections caused by Staphylococcus aureus, also referred to as Staphylococcus aureus bacteremia (SAB). ERADICATE reached its target enrolment of 390 patients. ERADICATE is the second of two phase 3 studies necessary for a regulatory filing of ceftobiprole in the U.S. The first study, TARGET, in patients with acute bacterial skin and skin structure infections (ABSSSI) reported positive results in 2019. If the results of the ERADICATE study are also positive, a New Drug Application will be submitted to the U.S. Food and Drug Administration (FDA). The U.S. is the larger potential market for ceftobiprole, considering the high incidence of MRSA (methicillin-resistant Staphylococcus aureus) infections in the U.S. Basilea's ceftobiprole phase 3 program is funded in part (up to USD 134.2 million, which is approximately 70% of the total potential program costs) with federal funds from the U.S. Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract number HHSO100201600002C.


ę S&P Capital IQ 2022
All news about BASILEA PHARMACEUTICA AG
04/27Basilea Pharmaceutica Licenses Antifungal Program From US-based Fox Chase
MT
04/27Basilea announces licensing of a novel first-in-class antifungal program from Fox Chase..
AQ
04/27Basilea Pharmaceutica AG Announces Licensing of Novel First-In-Class Antifungal Program..
CI
04/13Basilea shareholders approve all proposals of the board of directors at the annual gene..
GL
04/13Basilea Pharmaceutica Ltd. Approves Appointment of Leonard Kruimer as New Member of Boa..
CI
04/13Basilea's Oncology Drug Candidates Show Anti-Cancer Activity in Preclinical Trial
MT
04/13Basilea reports preclinical data on oncology drug candidates BAL0891, derazantinib and ..
AQ
04/13Basilea Pharmaceutica Ltd. Reports Preclinical Data on Oncology Drug Candidates BAL0891
CI
03/30BASILEA PHARMACEUTICA : Updated March 30, 2022
PU
03/16BASILEA PHARMACEUTICA : Shareholder letter EN
PU
More news
Analyst Recommendations on BASILEA PHARMACEUTICA AG
More recommendations
Financials
Sales 2022 126 M 127 M 127 M
Net income 2022 -44,3 M -44,6 M -44,6 M
Net Debt 2022 108 M 109 M 109 M
P/E ratio 2022 -8,65x
Yield 2022 -
Capitalization 367 M 366 M 370 M
EV / Sales 2022 3,78x
EV / Sales 2023 3,28x
Nbr of Employees 154
Free-Float 87,7%
Chart BASILEA PHARMACEUTICA AG
Duration : Period :
Basilea Pharmaceutica AG Technical Analysis Chart | BSLN | CH0011432447 | MarketScreener
Technical analysis trends BASILEA PHARMACEUTICA AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 31,00 CHF
Average target price 77,00 CHF
Spread / Average Target 148%
EPS Revisions
Managers and Directors
David Veitch Chief Executive Officer
Adesh Kaul Head-Corporate Development
Domenico Scala Chairman
Laurenz Kellenberger Chief Scientific Officer
Marc Engelhardt Head-Clinical Research
Sector and Competitors
1st jan.Capi. (M$)
BASILEA PHARMACEUTICA AG-24.24%366
MODERNA, INC.-46.35%54 199
LONZA GROUP AG-28.13%40 453
IQVIA HOLDINGS INC.-26.83%39 077
SEAGEN INC.-7.80%26 238
ICON PUBLIC LIMITED COMPANY-32.02%17 114